This page is an educational resource for Meredith employees and students provided as part of the College’s COVID-19 prevention efforts.

Vaccines have been distributed in North Carolina through a phased process. As April 7, all people age 16 and older will be eligible to receive the COVID-19 vaccine.

Employees and students are encouraged to visit the Wake County Health Department COVID vaccine website to learn more. The site includes information on the distribution process and FAQs. 

Frequently Asked Questions

Where can I get information about COVID-19 vaccines?

Will the College be providing any on-campus distribution of vaccinations to employees and students?

Meredith College held an on-campus vaccine clinic in April for those who qualify under the NC DHHS distribution plan.

Will the college be requiring employees and students to obtain a vaccination?
The College has not made any decisions regarding requiring the COVID vaccine in the future.

What should I know about the CDC/FDA pausing use of the Johnson & Johnson vaccine? 
On April 13, the CDC and FDA announced that out of an abundance of caution they are pausing use of the Johnson & Johnson (J&J) vaccine in order to review data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. More than 6.8 million doses of the J&J vaccine have been administered in the U.S.  People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.  Read the CDC/FDA statement.

Where can I find a vaccine location?

Surrounding county information:


Does quarantine guidance change for individuals who have been vaccinated?
Vaccinated individuals with an exposure to someone with suspected or confirmed COVID-19 are not required to quarantine if they meet all of the following criteria:

  • Are fully vaccinated (i.e., ≥2 weeks following receipt of the second dose in a 2-dose series, or ≥ 2 weeks following receipt of one dose of a single-dose vaccine)
  • Are within 3 months following receipt of the last dose in the series
  • Have remained asymptomatic since the current COVID-19 exposure

Note: The CDC has not systematically evaluated the efficacy of COVID-19 vaccines from manufacturers that have not sought an EUA in the United States. For the purposes of these quarantine criteria, considerations for accepting a vaccination series that is not FDA-authorized include whether the vaccine product has received emergency approval from the World Health Organization or authorization from a national regulatory agency. (Source: